Overview

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Status:
Recruiting

Trial end date:
2023-03-31

Target enrollment:

Participant gender:

Summary

This is a multicenter phase 2 open label study of pembrolizumab in patients with metastatic castrate resistant prostate cancer (mCRPC) with or without DNA damage repair defects.

Phase:

Phase 2

Details

Lead Sponsor:

University of California, San Francisco

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab